Strong Financial Performance

GSK plc has announced a notable increase in its first-quarter turnover for 2023, reaching £6.95 billion, which marks a 2% rise compared to the same period in 2024. When adjusted for constant exchange rates, this growth further escalates to 4%.

Earnings and Profit Surge

The company reported a significant 55% year-on-year increase in total earnings per share (EPS) to 39.7 pence, with core EPS also seeing a 4% rise to 44.9 pence. Operating profit witnessed a remarkable 49% jump to £2.2 billion from the first quarter of 2024, and the adjusted operating profit increased by 4% to £2.5 billion.

Strategic Progress and Future Outlook

"GSK continues to make strong progress, demonstrating the quality, strength, and resilience of our portfolio," stated CEO Emma Walmsley. She highlighted the strong sales contributions from Specialty Medicines, the company's largest business, and ongoing R&D progress, including two FDA product approvals secured this year and the acquisition of a promising new oncology asset. GSK is also focusing on preparing for the launches of Blenrep, Nucala, and depemokimab, alongside pivotal trials for potential new medicines in respiratory, oncology, HIV, and hepatitis.